Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma

P. H. Konits, D. A. van Echo, J. Aisner, D. Morris, P. H. Wiernik

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Thirty patients with refractory advanced breast cancer who had no prior treatment with doxorubicin or VP-16-213 received doxorubicin 45 mg/m2 I.V. on day 1 and VP-16-213 50 mg/m2 I.V. on days 1 through 5. Courses were repeated every 21 days when hematologic recovery permitted. Among 30 evaluable patients, one had a complete response and 11 had a partial response. Four patients had stabilization of their disease. There was thus a 40% response rate with a median response duration of 146 days (range 35-540). Toxicity included moderate to severe myelosuppression, infections, hemorrhage, and mucositis. In these poor prognoses in previously treated patients, the combination of doxorubicin and VP-16-213 appears to be an effective secondary treatment for metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)515-519
Number of pages5
JournalUnknown Journal
Issue number5
StatePublished - 1982
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma'. Together they form a unique fingerprint.

Cite this